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The objective of the present study was to determine the suitability of a swine breed with leptin resistance and predisposition to
obesity (the Iberian pig) as model for studies on metabolic syndrome and type 2 diabetes. Thus, six Iberian sows had ad libitum
access to food enriched with saturated fat (SFAD group; food consumption was estimated to be 4.5kg/animal/day) whilst four
females acted as controls and were fed with 2kg/animal/day of a commercial maintenance diet. After three months of diﬀerential
feeding, SFAD animals developed central obesity, dyslipidemia, insulin resistance and impaired glucose tolerance, and elevated
blood pressure; the ﬁve parameters associated with the metabolic syndrome. Thus, the current study characterizes the Iberian pig
as a robust, amenable, and reliable translational model for studies on nutrition-associated diseases.
1.Introduction
Obesity is currently declared a global pandemic by the
World Health Organization (WHO; http://www.who.int/
mediacentre/factsheets/fs311/en/index.html/), with at least
2.6 millions of people dying each year as a result of
being overweight or obese. The incidence of overweight
and obesity is dramatically rising and, according to WHO
predictions, approximately 2.3 billion of people will be
overweight and more than 700 million will be obese
by the year 2015 (http://www.who.int/features/factﬁles/obe-
sity/en/index.html). Furthermore, obesity predisposes to
the development of metabolic abnormalities, clustered in
the term metabolic syndrome. The metabolic syndrome is
characterized by the presence of at least three of ﬁve symp-
toms: central obesity, insulin resistance, impaired glucose
tolerance, dyslipidemia (increased triglyceridemia and low
plasmahigh-densitylipoproteins(HDL)cholesterol),and/or
hypertension [1–5]. Moreover, metabolic syndrome is the
main risk factor for developing type 2 diabetes [6, 7].
From these considerations, there is an urgent necessity for
increasing knowledge about obesity and its eﬀects. However,
mechanistical experimentation is not aﬀordable in human
beings and animal models are needed.
Most of the experimental studies on obesity and
metabolic disorders are carried out on laboratory rodents
despite the marked diﬀerences in metabolism and adipose
tissue biology between rodents and humans [8]. However,
diﬀerent species of large animals oﬀer numerous prof-
itable characteristics [9]. The pig is emerging rapidly as a
biomedical model for energy metabolism and obesity in
humans because it shares several similarities with humans:
omnivorous habits, propensity to sedentary behaviour and
fattening, and similar metabolic and cardiovascular features
[10–13].
The objective of the present study was to determine
the propensity of a swine breed with predisposition to
obesity (the Iberian pig) for developing features of metabolic2 The Scientiﬁc World Journal
syndrome and type 2 diabetes. The Iberian pig is worldwide
known for the production of a unique highly priced dry-
cured product, the Iberian ham, with a unique taste due to
its abundance in intramuscular fat. In fact, the Iberian pig
has a high potential for fat accumulation under its skin and
among the muscular ﬁbres [14], due to a polymorphism of
the leptin receptor gene (LEPR)w i t he ﬀects on food intake,
body weight, and fat deposition [15, 16]. As a consequence,
Iberian LEPR allele increases insatiability and obesity. Such
state in human medicine is called leptin resistance, the
failure, in obese individuals with elevated leptin levels, for
suppressing feeding and mediating weight loss [17, 18]d u e
to LEPR polymorphisms associated with food preferences
and obesity [19]. Thus, having in mind these considerations,
our hypothesis was that eating excess and obesity in Iberian
pigs would develop a condition similar to the human
metabolic syndrome. The ﬁnal purpose of our study was
to characterize a suitable pig model for studies on leptin
resistance, obesity, metabolic syndrome, and type 2 diabetes.
2.MaterialandMethods
2.1. Animals and Handling. T e na d u l tI b e r i a ns o w s( 2 - 3
years old) were used. All the animals had been genotyped
for polymorphism on LEPR gene with protocols previously
described [15] and found to be homozygous for the allele
LEPRc.1987T, previously associated with increased appetite,
fattening, and bodyweight [15, 16]. The experimental pro-
cedure was performed in collective pens at the facilities
of the INIA Animal Laboratory Unit (Madrid, Spain).
The INIA Animal Unit meets the requirements of the
European Union for Scientiﬁc Procedure Establishments.
The experiment was carried out under Project License from
the INIA Scientiﬁc Ethic Committee. Animal manipulations
were performed according to the Spanish Policy for Animal
Protection RD1201/05, which meets the European Union
Directive 86/609 about the protection of animals used in
experimentation.
Animals were fed, prior to the experimental procedure,
with a standard grain-based diet fulﬁlling their daily main-
tenance requirements (2kg/animal/day); mean values of the
diet were 89.8% of dry matter, 15.1% of crude protein,
and 2.8% of polyunsaturated fat. At the beginning of the
experimental procedure, the animals were divided in two
diﬀerent pens corresponding to diﬀerent diets. Four of the
s o w sa c t e da sc o n t r o l s( c o n t r o lg r o u po rg r o u pC )a n d
continued being fed with the same diet and amount. The
remaining six animals had ad libitum access to the same
diet but enriched with saturated fat (3.7%; saturated fat
ad libitum group or group SFAD); during the experimental
period (100 days), food consumption was estimated to be
4.5kg/animal/day.
2.2. Evaluation of Body Weight, Size, and Fatness. Body
weight, thoracic and abdominal circumferences (obtained
with a measuring tape) and back-fat depth (ultrasonically
determined at P2 point, at the level of the head of the
last right rib) were measured at days 0, 45, and 90 after
starting the diﬀerential feeding. Thoracic circumference has
been shown to be predictive for the amount of carcass fat
whilst abdominal circumference is predictive of visceral and
subcutaneous fat, obtained by quantitative dissection, in pigs
and minipigs [20–22].
2.3. Evaluation of Metabolic Status. Blood samples were
drawn concurrently with body measures, after a fasting pe-
riod of around 18 hours, by jugular venopuncture with 5mL
sterile heparin blood vacuum tubes (Vacutainer Systems
Europe). Immediately after recovery, the blood was cen-
trifuged at 1500g for 15min and the plasma was separated
a n ds t o r e da t−20◦C until assayed.
Parameters related to metabolism of lipids (triglyc-
erides,totalcholesterol,high-densitylipoproteinscholesterol
(HDL-c) and low-density lipoproteins cholesterol (LDL-c))
were measured with a clinical chemistry analyzer (Screen
Point, Hospitex Diagnostics, Sesto Fiorentino, Italy). Plasma
HDL-c ratio and LDL-c ratio were calculated by dividing
total cholesterol by HDL-c and LDL-c concentrations,
respectively; plasma LDL-c/HDL-c ratio was obtained by
dividing LDL-c levels by HDL-c concentrations.
Parameters related to metabolism of glucose (glucose
and insulin) were measured with a clinical chemistry ana-
lyzer for glucose (Screen Point, Hospitex Diagnostics, Sesto
Fiorentino, Italia) and with a Porcine Insulin ELISA kit
(Mercodia AB, Uppsala, Sweden), respectively. The assay
sensitivity was 0.26UI/L; the intraassay variation coeﬃcient
was 3.5%.
Possible changes in β-cell function and insulin resistance
(IR) during the experimental protocol were assessed by
the homeostasis model assessment (HOMA), using the
equations HOMA-IR = (FINS × FPG)/22.5 to assess insulin
resistance [23] and HOMA-β = (20 × FINS)/(FPG − 3.5) to
assess beta cell function [24]; FINS is fasting plasma insulin
concentration in U/L and FPG is fasting plasma glucose
concentration in mmol/L. Furthermore, an oral glucose
tolerance test (OGTT) was performed at day 100 after the
beginning of experimental procedure, by using the protocol
describedbyLiuetal.[25].Inbrief,animalsweregiven2g/kg
live weight of D-glucose, after a fasting period of around
18 hours, by gavage through a gastric tube inserted into
the stomach. Blood samples were obtained for determining
plasma glucose and insulin at 0, 15, 30, 60, 90, and 120
minutesafterglucoseadministration,centrifuged,andstored
at −20◦C until assayed.
2.4. Measurement of Cardiovascular Features. Blood pres-
sures were monitored at the beginning and end of the ex-
perimentalperiod(days0and100)byusingatailcuﬀsphyg-
momanometer.
2.5. Statistical Analyses. Eﬀects of diet on body, metabolic
and cardiovascular features were assessed by analysis of vari-
anceforrepeatedmeasures(split-plotANOVA).Resultswere
expressedasthemean ±SEM,andstatisticalsigniﬁcancewas
accepted from P<0.05.The Scientiﬁc World Journal 3
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Figure 1:Changesinmeanliveweight(a),back-fatdepth(b),andabdominalandthoraciccircumferences((c)and(d),resp.)overtimeafter
diﬀerential feeding in control sows (grey bars) and sows with ad libitum access to a diet enriched with saturated fat (black bars). Asterisks
indicate signiﬁcant diﬀerences.
3. Results
3.1. Eﬀects of Diet on Body Weight and Fatness: Central
Obesity. Livebodyweight,back-fatdepth,andmeasurement
of thoracic and abdominal circumferences were similar
between groups at starting the diﬀerential feeding period
(Figure 1). Values remained unchanged in control animals
throughout the experimental period (with increases around
750g for weight, 3cm for the circumferences, and 1mm
for back-fat depth) but increased with time in the group
SFAD (around 35kg for weight, 13 and 6cm for thoracic
and abdominal circumferences, resp., and 18mm for back-
fat depth; P<0.05 for body weight and circumferences
and P<0.005 for back-fat depth). Diﬀerences in body
weight and thoracic circumferences between groups reached
statistical signiﬁcance from day 45 onwards (P<0.05),
whilst abdominal circumference and back-fat content were
diﬀerentonlyatday90(P<0.05andP<0.001,resp.).Thus,
animals in the SFAD group showed obesity and, speciﬁcally,
central obesity after three months of diﬀerential feeding, a
ﬁrst symptom of metabolic syndrome.
3.2.EﬀectsofDietonMetabolicFeatures:Dyslipidemia,Insulin
Resistance, and Glucose Intolerance. Assessment of plasma
indexesoflipidmetabolismshowednosigniﬁcantdiﬀerences
between groups at the beginning of the experimental proto-
col (Figure 2). After 45 days, diﬀerences were not signiﬁcant.
However, after 90 days, SFAD group had signiﬁcantly (P<
0.05) higher plasma levels of triglycerides and cholesterol
and higher ratios of HDL-c (total cholesterol divided by
HDL-c) and LDL-c/HDL-c (LDL-c levels divided by HDL-
c concentrations), since the increase in total cholesterol was
accompanied by the increase in LDL-C but not in HDL-
c. Such enlarged triglyceridemia with low HDL-c ratios
evidenced dyslipidemia, which is a second symptom of
metabolic syndrome.
There were no signiﬁcant diﬀerences between groups
in glucose and insulin levels at the beginning of the study
(Figure 3). Analysis of plasma glucose showed higher, but
not signiﬁcant, levels in SFAD group after 45 and 90 days
of diﬀerential feeding. Conversely, plasma insulin concen-
trations showed diﬀerent proﬁles between groups. Insulin
level did not signiﬁcantly diﬀer in group C throughout4 The Scientiﬁc World Journal
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Figure 2: Changes in plasma concentration of triglycerides (a), cholesterol (b), LDL-c (c), and HDL-c (d) over time after diﬀerential feeding
in control sows (grey bars) and sows with ad libitum access to a diet enriched with saturated fat (black bars). Asterisks indicate signiﬁcant
diﬀerences.
the experimental period, but plasma insulin concentration
increased at day 45 in the group SFAD (P<0.05) and
decreased again at day 90 (P<0.01).
Both HOMA-IR and HOMA-β indexes remained nearly
unchanged throughout the period of study in the group
C. Conversely, both indexes increased signiﬁcantly after 45
days in the group SFAD (P<0.01 for both) and returned
t ot h ec o n t r o lv a l u e sa td a y9 0( P<0.05 and P<0.01,
resp.), when these indexes reached numerically higher but
not statistically diﬀerent values to control females. Thus,
bothHOMA-IRandHOMA-βwerehigherinSFADatday45
(P<0.05 and P<0.01, resp.), evidencing insulin resistance,
the third symptom of metabolic syndrome,a n dimpaired β-
cell function,r e s p e c t i v e l y .
T h eo r a lg l u c o s et o l e r a n c et e s t( O G T T ;F i g u r e4) showed
that, in control animals, the plasma glucose levels started
to increase after 15 minutes and reached a peak around
one hour later (P<0.01) for rapidly declining to starting
values afterwards. Assessment of insulin levels in these pigs
evidenced a well-characterized acute insulin response. In
contrast, the OGTT showed a deﬁcient glucose elimination
(i.e., glucose intolerance, fourth symptom of the metabolic
syndrome) in the group SFAD, since glucose levels did not
decrease for the period of study. Moreover, SFAD sows had
a deﬁcient insulin secretion, conﬁrming the diet-induced β-
cell dysfunction suggested by prior changes in HOMA-β and
evidencing the prodrome of type 2 diabetes.
3.3. Eﬀects of Diet on Cardiovascular Features: Hypertension.
Assessment of blood pressure showed similar values in both
groups at the beginning of study (Figure 5). At the end of
the treatment, all the parameters remained stable in control
femalesbutincreasedinobesefemales;thesediﬀerenceswere
statistically signiﬁcant for diastolic and mean blood pressure
(P<0.01 and P<0.005, resp.) evidencing a hypertensive
state, the ﬁfth symptom of a metabolic syndrome.
4. Discussion
The results found in the present study indicate that adult
females of the Iberian pig, a swine breed with leptin
resistance, can develop the prodrome of metabolic syndrome
and type 2 diabetes when allowed to freely eat a diet enriched
with saturated fat. This feature was found as early as in
three months. Thus, current experiment reinforces previous
evidences about the susceptibility of this breed to changes in
nutritional inputs [26, 27] and characterizes the Iberian pigThe Scientiﬁc World Journal 5
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Figure 3: Changes in plasma concentration of glucose (a), insulin (b), and indexes of HOMA-IR and HOMA-β ((c) and (d), resp.) over
time after diﬀerential feeding in control sows (grey bars) and sows with ad libitum access to a diet enriched with saturated fat (black bars).
Asterisks indicate signiﬁcant diﬀerences.
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Figure 4: Changes in plasma concentration of glucose (continuous line) and insulin (discontinuous line) over time after oral administration
of 2g/kg live weight of D-glucose in control sows (a) and sows with ad libitum access to a diet enriched with saturated fat (b).
as a robust, amenable, and reliable translational model for
studies on nutrition-associated diseases.
In these three months, pigs developed alterations in the
ﬁve parameters associated with the metabolic syndrome.
Obesity was associated with diﬀerent degrees of dyslipi-
demia, insulin resistance and impaired glucose tolerance,
and elevated blood pressure. Such ﬁnding reinforces the
strength of our model. There are no other animal models
consistently showing four or more risk factors of the
syndrome [13]. Establishment of the ﬁve parameters of
the metabolic syndrome has been previously found in the
Ossabaw pig [21]. However, it is known that Ossabaw pigs
are derived from the Iberian pigs introduced by Spanish and
Portuguese colonizers, since there were no pigs in the New
World before their arrival in the 15th century. Iberian pigs,
conversely to Ossabaw pigs, are numerous (the estimated
census of breeding sows, only in Spain, is around 238.000)
and, hence, easy to get and reasonably priced. Finally, the
robustness of the model is also reinforced by the fact that
homeostatic changes were found when feeding the sows with6 The Scientiﬁc World Journal
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Figure 5: Changes in systolic (a), diastolic (b), and mean (c) blood pressures over time after diﬀerential feeding in control sows (grey bars)
and sows with ad libitum access to a diet enriched with saturated fat (black bars). Asterisks indicate signiﬁcant diﬀerences.
diets having a considerably lower level of fat content and
energy than provided in previous studies with other swine
breeds [21, 28, 29].
The eﬀects of the diet on body weight, size, and fat
content were remarkable and were observed very early
after starting the diﬀerentiated feeding, but the pattern of
fattening seemed to be aﬀected by time. Diﬀerences in
body measurements were ﬁrstly found in body weight and
thoracic circumference and thereafter in subcutaneous fat
and abdominal circumference. Thus, we can assume that
fat deposition when there is a positive energy balance is
ﬁrstly intramuscular in the whole carcass. At later stages,
fat deposition is also subcutaneous and, which is more
important, visceral. Visceral deposition of fat gives way to
central obesity, the former and causal factor for metabolic
syndrome.
The current study also indicates that eﬀects on carbo-
hydrate metabolism were found earlier than the eﬀects on
lipid metabolism. There were no signiﬁcant diﬀerences in
plasma glucose concentrations throughout the study as it
has been described in the ﬁrst stages of the human disease
[30]. However, high intake of saturated fat impaired glucose
regulation and induced some degree of insulin resistance
and altered β-cell function (main parameters of metabolic
syndrome and type 2 diabetes) at 45 days after starting
the diﬀerentiated feeding. This ﬁnding is in agreement with
previous studies in rats also fed with saturated fat, which
developedinsulinresistanceinaveryshortterm[31–33],but
also with observational data in human beings [34]. Animals
of the current experiment were capable of counterbalancing
thereafter the prodrome of metabolic syndrome and type 2
diabetes as evidenced by the plasma insulin concentrations
and HOMA-IR and HOMA-β found at day 90. However,
the equilibrium was unstable and the challenge of glucose
during the OGTT evidenced the weakness of this adaptation;
animals confronted with such acute high supply of glucose
showed glucose intolerance, other parameter of the metabolic
syndrome,a n da l t e r a t i o n si nβ-cell function, which are the
main cause of type 2 diabetes [35].
Establishment of insulin resistance has been linked to
elevated levels of triglycerides in blood and tissues [32,
36–38], and hypertriglyceridemia is another parameter of
metabolic syndrome. However, in the current study, hyper-
triglyceridemia was found in a later stage than insulin
resistance; simultaneously with the increase in visceral fat,
which conﬁrms earlier hypothesis indicating that hyper-
triglyceridemia is related primarily to the amount of such
kind of fat [39]. Obese sows of this study showed a well-
established dyslipidemic proﬁle with signiﬁcantly higher
plasma triglycerides but also total cholesterol and LDL-
c/HDL-c ratio, suggesting higher levels of LDL-c than HDL-
c. These features resemble hyperlipidemia type 2 (increased
total cholesterol and LDL-c) and the so-called lipid triad
in human medicine (elevated triglycerides, elevated LDL-c,
and low HDL-c), [40, 41]. The rise of cholesterol caused by
elevations of LDL-c may occur both in type 1 and type 2
diabeticpatients;however,concurrentlylowHDL-clevelsare
indicative of obese individuals with type 2 diabetes [42].
Alterations of carbohydrate and lipoprotein metabolism
were also early identiﬁed as risk factors for hypertension, the
ﬁfth symptom in the metabolic syndrome [43, 44]. In our
study, higher blood pressures were also found in the obese
sows, indicating that they have a hyperdynamic circulatory
state,similartopreviouslydescribedinOssabawpigs[45].In
our study, changes were mainly found in diastolic pressure,
coincidentally with studies in human beings [46, 47].
Hyperdynamic circulatory states, characterized by increased
blood pressure, total blood volume, cardiac output, and
tissue metabolic demand, have been hypothesized to be the
main cause of cardiac and hemodynamic alterations in obese
individuals [48–50].
In conclusion, this study indicates that Iberian pigs
freely eating saturated fat diets are prone to central obesity,
abnormalities in insulin-glucose regulation, dyslipidemia,
and elevated blood pressure, the symptoms of metabolic
syndrome. Thus, the current data characterize the Iberian
pig as a robust, amenable, and reliable translational model
for studies on nutrition-associated diseases.
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